Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tezspire All Set To Tackle Big Biologic Rivals In Severe Asthma

EU Approval Granted For AstraZeneca's Amgen-Partnered Therapy

Executive Summary

With a European approval in the bag for Tezspire, AstraZeneca is looking for quick and successful launches of the severe asthma drug so it can mount a challenge to the other biologics in the space, notably Sanofi and Regeneron’s Dupixent.

You may also be interested in...



Airsupra Could Help Revive AstraZeneca's Respiratory Fortunes

The US Food and Drug Administration has approved AstraZeneca and Avillion’s respiratory drug Airsupra, making it the only rescue medication cleared for as-needed use to reduce risk of asthma exacerbations.

AstraZeneca’s Fasenra Future Weakened By Pivotal Eosinophilic Esophagitis Trial Flop

The major’s monoclonal antibody drug missed one of two primary endpoints in a late-stage eosinophilic esophagitis trial in the second setback this year to plans for label expansion beyond the asthma maintenance setting.

AstraZeneca’s Triple Regulatory Wins For Enhertu, Tezspire And Ultomiris Herald Sales Boost

The major has won US priority review for a commercially crucial label expansion of its breast cancer drug Enhertu while Tezspire and Ultomiris attracted positive CHMP opinions across the Atlantic.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel